Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Sunitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 113 Kidney Neoplasms 36 Neoplasms 31 Neoplasm Metastasis 27 Breast Neoplasms 27 Gastrointestinal Stromal Tumors 26 Carcinoma, Non-Small-Cell Lung 20 Prostatic Neoplasms 12 Urinary Bladder Neoplasms 11 Glioblastoma 11 Colorectal Neoplasms 11 Pancreatic Neoplasms 9 Lung Neoplasms 9 Carcinoma 9 Brain Neoplasms 9 Melanoma 8 Stomach Neoplasms 7 Sarcoma 7 Neuroendocrine Tumors 7 Carcinoma, Hepatocellular 7 Adenoma, Islet Cell 7 Thyroid Neoplasms 6 Small Cell Lung Carcinoma 6 Ovarian Neoplasms 6 Clear-cell metastatic renal cell carcinoma 6 Uveal Melanoma 5 Solid Tumors 5 Multiple Myeloma 5 Liver Neoplasms 5 Leukemia, Myeloid, Acute 5

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00821327 2016-10-25

Gemzar, Cisp, Sunitinib Urothelial Ca

US Oncology Research

Phase 2 Completed

36 enrolled 9 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡